Tumor-Induced Osteomalacia

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Tumor-induced osteomalacia (TIO) is a rare, paraneoplastic disease that can be difficult to distinguish from genetic forms of hypophosphatemia and severe osteomalacia. The hallmark of TIO, and its genetic phenocopies, is renal phosphate wasting and abnormal vitamin D metabolism; specifically, lack of compensatory increase in 1,25-dihydroxyvitamin D (1,25(OH)2D3) in response to hypophosphatemia. Ultimately, unchecked renal phosphorus excretion and relative 1,25(OH)3 deficiency leads to osteomalacia, a metabolic bone disease characterized by a failure of mineralization and resultant weak, painful bones. Physical examination often reveals bone pain, especially with palpation of the anterior tibia and sternum. In children, long bone deformity, lower extremity bowing, and chest wall deformity is observed. If TIO is suspected, an extensive examination for masses or nodules is warranted, concentrating on soft tissues adjacent to long bones, distal extremities, the oral cavity and jaw, and the groin. Hypophosphatemia secondary to renal phosphate wasting has a wide differential diagnosis. These disorders can result from primary renal defects, overproduction of the phosphaturic hormone, FGF23, from normal or dysplastic bone and ectopic production of FGF23 or other phosphaturic proteins from tumors. Most tumors responsible for TIO are of mesenchymal origin, and are found in bone or soft tissue. The most common sites are in the long bones and extremities, but nasopharynx, sinuses, and groin are other locations. TIO is only definitively treated by identification and resection of the causative tumor. In addition, recently, the calcium-sensing receptor agonist, cinacalcet, has been shown to be an effective adjuvant in the treatment of TIO.

Original languageEnglish (US)
Title of host publicationPrinciples of Bone Biology, Two-Volume Set
PublisherElsevier Inc.
Pages1549-1560
Number of pages12
Volume2
ISBN (Print)9780123738844
DOIs
StatePublished - 2008

Fingerprint

Tumors
Bone
Hypophosphatemia
Bone and Bones
Osteomalacia
Groin
Kidney
Jetties
Bones of Lower Extremity
Extremities
Phosphates
Calcium-Sensing Receptors
Neoplasms
Sternum
Nasopharynx
Metabolic Bone Diseases
Palpation
Thoracic Wall
Rare Diseases
Jaw

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mammen, J. S., & Jan De Beur, S. M. (2008). Tumor-Induced Osteomalacia. In Principles of Bone Biology, Two-Volume Set (Vol. 2, pp. 1549-1560). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-373884-4.00079-3

Tumor-Induced Osteomalacia. / Mammen, Jennifer S; Jan De Beur, Suzanne M.

Principles of Bone Biology, Two-Volume Set. Vol. 2 Elsevier Inc., 2008. p. 1549-1560.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mammen, JS & Jan De Beur, SM 2008, Tumor-Induced Osteomalacia. in Principles of Bone Biology, Two-Volume Set. vol. 2, Elsevier Inc., pp. 1549-1560. https://doi.org/10.1016/B978-0-12-373884-4.00079-3
Mammen JS, Jan De Beur SM. Tumor-Induced Osteomalacia. In Principles of Bone Biology, Two-Volume Set. Vol. 2. Elsevier Inc. 2008. p. 1549-1560 https://doi.org/10.1016/B978-0-12-373884-4.00079-3
Mammen, Jennifer S ; Jan De Beur, Suzanne M. / Tumor-Induced Osteomalacia. Principles of Bone Biology, Two-Volume Set. Vol. 2 Elsevier Inc., 2008. pp. 1549-1560
@inbook{0e3e49cd64614f97a52e4a42de8f9e63,
title = "Tumor-Induced Osteomalacia",
abstract = "Tumor-induced osteomalacia (TIO) is a rare, paraneoplastic disease that can be difficult to distinguish from genetic forms of hypophosphatemia and severe osteomalacia. The hallmark of TIO, and its genetic phenocopies, is renal phosphate wasting and abnormal vitamin D metabolism; specifically, lack of compensatory increase in 1,25-dihydroxyvitamin D (1,25(OH)2D3) in response to hypophosphatemia. Ultimately, unchecked renal phosphorus excretion and relative 1,25(OH)3 deficiency leads to osteomalacia, a metabolic bone disease characterized by a failure of mineralization and resultant weak, painful bones. Physical examination often reveals bone pain, especially with palpation of the anterior tibia and sternum. In children, long bone deformity, lower extremity bowing, and chest wall deformity is observed. If TIO is suspected, an extensive examination for masses or nodules is warranted, concentrating on soft tissues adjacent to long bones, distal extremities, the oral cavity and jaw, and the groin. Hypophosphatemia secondary to renal phosphate wasting has a wide differential diagnosis. These disorders can result from primary renal defects, overproduction of the phosphaturic hormone, FGF23, from normal or dysplastic bone and ectopic production of FGF23 or other phosphaturic proteins from tumors. Most tumors responsible for TIO are of mesenchymal origin, and are found in bone or soft tissue. The most common sites are in the long bones and extremities, but nasopharynx, sinuses, and groin are other locations. TIO is only definitively treated by identification and resection of the causative tumor. In addition, recently, the calcium-sensing receptor agonist, cinacalcet, has been shown to be an effective adjuvant in the treatment of TIO.",
author = "Mammen, {Jennifer S} and {Jan De Beur}, {Suzanne M}",
year = "2008",
doi = "10.1016/B978-0-12-373884-4.00079-3",
language = "English (US)",
isbn = "9780123738844",
volume = "2",
pages = "1549--1560",
booktitle = "Principles of Bone Biology, Two-Volume Set",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Tumor-Induced Osteomalacia

AU - Mammen, Jennifer S

AU - Jan De Beur, Suzanne M

PY - 2008

Y1 - 2008

N2 - Tumor-induced osteomalacia (TIO) is a rare, paraneoplastic disease that can be difficult to distinguish from genetic forms of hypophosphatemia and severe osteomalacia. The hallmark of TIO, and its genetic phenocopies, is renal phosphate wasting and abnormal vitamin D metabolism; specifically, lack of compensatory increase in 1,25-dihydroxyvitamin D (1,25(OH)2D3) in response to hypophosphatemia. Ultimately, unchecked renal phosphorus excretion and relative 1,25(OH)3 deficiency leads to osteomalacia, a metabolic bone disease characterized by a failure of mineralization and resultant weak, painful bones. Physical examination often reveals bone pain, especially with palpation of the anterior tibia and sternum. In children, long bone deformity, lower extremity bowing, and chest wall deformity is observed. If TIO is suspected, an extensive examination for masses or nodules is warranted, concentrating on soft tissues adjacent to long bones, distal extremities, the oral cavity and jaw, and the groin. Hypophosphatemia secondary to renal phosphate wasting has a wide differential diagnosis. These disorders can result from primary renal defects, overproduction of the phosphaturic hormone, FGF23, from normal or dysplastic bone and ectopic production of FGF23 or other phosphaturic proteins from tumors. Most tumors responsible for TIO are of mesenchymal origin, and are found in bone or soft tissue. The most common sites are in the long bones and extremities, but nasopharynx, sinuses, and groin are other locations. TIO is only definitively treated by identification and resection of the causative tumor. In addition, recently, the calcium-sensing receptor agonist, cinacalcet, has been shown to be an effective adjuvant in the treatment of TIO.

AB - Tumor-induced osteomalacia (TIO) is a rare, paraneoplastic disease that can be difficult to distinguish from genetic forms of hypophosphatemia and severe osteomalacia. The hallmark of TIO, and its genetic phenocopies, is renal phosphate wasting and abnormal vitamin D metabolism; specifically, lack of compensatory increase in 1,25-dihydroxyvitamin D (1,25(OH)2D3) in response to hypophosphatemia. Ultimately, unchecked renal phosphorus excretion and relative 1,25(OH)3 deficiency leads to osteomalacia, a metabolic bone disease characterized by a failure of mineralization and resultant weak, painful bones. Physical examination often reveals bone pain, especially with palpation of the anterior tibia and sternum. In children, long bone deformity, lower extremity bowing, and chest wall deformity is observed. If TIO is suspected, an extensive examination for masses or nodules is warranted, concentrating on soft tissues adjacent to long bones, distal extremities, the oral cavity and jaw, and the groin. Hypophosphatemia secondary to renal phosphate wasting has a wide differential diagnosis. These disorders can result from primary renal defects, overproduction of the phosphaturic hormone, FGF23, from normal or dysplastic bone and ectopic production of FGF23 or other phosphaturic proteins from tumors. Most tumors responsible for TIO are of mesenchymal origin, and are found in bone or soft tissue. The most common sites are in the long bones and extremities, but nasopharynx, sinuses, and groin are other locations. TIO is only definitively treated by identification and resection of the causative tumor. In addition, recently, the calcium-sensing receptor agonist, cinacalcet, has been shown to be an effective adjuvant in the treatment of TIO.

UR - http://www.scopus.com/inward/record.url?scp=84882537730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882537730&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-373884-4.00079-3

DO - 10.1016/B978-0-12-373884-4.00079-3

M3 - Chapter

AN - SCOPUS:84882537730

SN - 9780123738844

VL - 2

SP - 1549

EP - 1560

BT - Principles of Bone Biology, Two-Volume Set

PB - Elsevier Inc.

ER -